DossierENTITY

Candid Therapeutics

Coverage of Candid Therapeutics in the Nexus archive.

Earliest in view: May 4 · 13:58 UTCMost recent: May 4 · 13:58 UTC

Co-mentioned in this coverage

Recent coverage

HEALTHMay 4 · 13:58 UTCSTAT NEWS
STAT+: Pharmalittle: We’re reading about an abortion pill controversy, another UCB deal, and more news
Two drugmakers, Danco Laboratories and GenBioPro, have asked the US Supreme Court to restore mail-order access to the abortion pill mifepristone, while UCB has acquired Candid Therapeutics in a deal worth $2.2 billion to expand its presence in autoimmune disease therapies.